Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
1.3 billion tobacco users worldwide (WHO). Leading preventable cause of death globally (8 million deaths/year). 6-month quit rates with best available treatments (varenicline) are approximately 25-35%.
NRT (patches, gum, lozenge), varenicline (Champix), bupropion, behavioral counseling. Even with combination therapy, long-term abstinence rates are modest.
Psilocybin-assisted therapy combined with CBT for smoking cessation at Johns Hopkins showed remarkable quit rates. The combination of powerful motivational insights during the psychedelic experience with structured behavioral change support appears synergistic.
Johnson et al. (2014): 80% abstinence at 6 months (open-label pilot, n=15). Johnson et al. (2017): 67% confirmed abstinent at 12 months. These rates substantially exceed any current pharmacotherapy.